These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
273 related articles for article (PubMed ID: 34607193)
1. Hepatitis C virus cascade of care among people who inject drugs in Australia: Factors associated with testing and treatment in a universal healthcare system. Gibbs D; Price O; Grebely J; Larney S; Sutherland R; Read P; Butler K; Degenhardt L; Peacock A Drug Alcohol Depend; 2021 Nov; 228():109050. PubMed ID: 34607193 [TBL] [Abstract][Full Text] [Related]
2. Estimating the Consensus hepatitis C Cascade of Care among people who inject drugs in Australia: Pre and post availability of direct acting antiviral therapy. Iversen J; Dore GJ; Starr M; Catlett B; Cunningham P; Geddes L; Maher L Int J Drug Policy; 2020 Sep; 83():102837. PubMed ID: 32645585 [TBL] [Abstract][Full Text] [Related]
3. Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage study. Valerio H; Alavi M; Conway A; Silk D; Treloar C; Martinello M; Milat A; Dunlop A; Murray C; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Stevens A; Prain B; Hayllar J; Reid D; Montebello M; Wade A; Christmass M; Cock V; Dore GJ; Grebely J; Int J Drug Policy; 2022 Jul; 105():103706. PubMed ID: 35533635 [TBL] [Abstract][Full Text] [Related]
4. Progress Towards Elimination of Hepatitis C Infection Among People Who Inject Drugs in Australia: The ETHOS Engage Study. Valerio H; Alavi M; Silk D; Treloar C; Martinello M; Milat A; Dunlop A; Holden J; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Hayllar J; Reid D; Gorton C; Lam T; Dore GJ; Grebely J Clin Infect Dis; 2021 Jul; 73(1):e69-e78. PubMed ID: 32421194 [TBL] [Abstract][Full Text] [Related]
5. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada. Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB; Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989 [TBL] [Abstract][Full Text] [Related]
6. A Testing Campaign Intervention Consisting of Peer-Facilitated Engagement, Point-of-Care HCV RNA Testing, and Linkage to Nursing Support to Enhance Hepatitis C Treatment Uptake among People Who Inject Drugs: The ETHOS Engage Study. Conway A; Valerio H; Alavi M; Silk D; Treloar C; Hajarizadeh B; Marshall AD; Martinello M; Milat A; Dunlop A; Murray C; Prain B; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Hayllar J; Reid D; Gorton C; Lam T; Christmass M; Wade A; Montebello M; Dore GJ; Grebely J; Viruses; 2022 Jul; 14(7):. PubMed ID: 35891535 [TBL] [Abstract][Full Text] [Related]
7. Association Between Opioid Agonist Therapy and Testing, Treatment Uptake, and Treatment Outcomes for Hepatitis C Infection Among People Who Inject Drugs: A Systematic Review and Meta-analysis. Grebely J; Tran L; Degenhardt L; Dowell-Day A; Santo T; Larney S; Hickman M; Vickerman P; French C; Butler K; Gibbs D; Valerio H; Read P; Dore GJ; Hajarizadeh B Clin Infect Dis; 2021 Jul; 73(1):e107-e118. PubMed ID: 32447375 [TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study. Bajis S; Grebely J; Hajarizadeh B; Applegate T; Marshall AD; Ellen Harrod M; Byrne J; Bath N; Read P; Edwards M; Gorton C; Hayllar J; Cock V; Peterson S; Thomson C; Weltman M; Jefferies M; Wood W; Haber P; Ezard N; Martinello M; Maher L; Dore GJ; J Viral Hepat; 2020 Mar; 27(3):281-293. PubMed ID: 31698545 [TBL] [Abstract][Full Text] [Related]
9. Investigating the sociodemographic and behavioural factors associated with hepatitis C virus testing amongst people who inject drugs in England, Wales and Northern Ireland: A quantitative cross-sectional analysis. Yuan JM; Croxford S; Viviani L; Emanuel E; Phipps E; Desai M Int J Drug Policy; 2022 Nov; 109():103821. PubMed ID: 35994940 [TBL] [Abstract][Full Text] [Related]
10. Awareness of hepatitis C virus infection status among people who inject drugs in a setting of universal direct-acting antiviral therapy: The ETHOS Engage study. Valerio H; Conway A; Alavi M; Treloar C; Silk D; Murray C; Henderson C; Amin J; Read P; Degenhardt L; Christmass M; Montebello M; Dore GJ; Grebely J; Int J Drug Policy; 2022 Dec; 110():103876. PubMed ID: 36240657 [TBL] [Abstract][Full Text] [Related]
11. Hepatitis C treatment uptake among people who inject drugs in Oslo, Norway: A registry-based study. Malme KB; Ulstein K; Finbråten AK; Wüsthoff LEC; Kielland KB; Hauge J; Dalgard O; Midgard H Int J Drug Policy; 2023 Jun; 116():104044. PubMed ID: 37149914 [TBL] [Abstract][Full Text] [Related]
12. Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade. Scott N; Doyle JS; Wilson DP; Wade A; Howell J; Pedrana A; Thompson A; Hellard ME Int J Drug Policy; 2017 Sep; 47():107-116. PubMed ID: 28797497 [TBL] [Abstract][Full Text] [Related]
13. Incidence of primary hepatitis C virus infection among people who inject drugs in Australia pre- and post-unrestricted availability of direct acting antiviral therapies. Iversen J; Wand H; McManus H; Dore GJ; Maher L Addiction; 2023 May; 118(5):901-911. PubMed ID: 36524842 [TBL] [Abstract][Full Text] [Related]
14. Exploring hepatitis C virus testing and treatment engagement over time in Melbourne, Australia: a study protocol for a longitudinal cohort study (EC-Experience Cohort study). O'Keefe D; Gunn J; Ryan K; Djordjevic F; Kerr P; Gold J; Elsum I; Layton C; Chan K; Dietze P; Higgs P; Doyle J; Stoové MA; Hellard M; Pedrana AE BMJ Open; 2022 Jan; 12(1):e057618. PubMed ID: 34983773 [TBL] [Abstract][Full Text] [Related]
15. Evaluating the prevalence of current hepatitis C infection and treatment among Aboriginal and Torres Strait Islander peoples who inject drugs in Australia: The ETHOS engage study. Hobday S; Valerio H; Combo T; Monaghan R; Scott C; Silk D; Murray C; Read P; Henderson C; Degenhardt L; Treloar C; Dore GJ; Grebely J; Martinello M; Drug Alcohol Rev; 2023 Nov; 42(7):1617-1632. PubMed ID: 37556376 [TBL] [Abstract][Full Text] [Related]
16. Is hepatitis C virus (HCV) elimination achievable among people who inject drugs in Tijuana, Mexico? A modeling analysis. Marquez LK; Cepeda JA; Bórquez A; Strathdee SA; Gonzalez-Zúñiga PE; Fleiz C; Rafful C; Garfein RS; Kiene SM; Brodine S; Martin NK Int J Drug Policy; 2021 Feb; 88():102710. PubMed ID: 32165050 [TBL] [Abstract][Full Text] [Related]
17. Concordance between self-reported and current hepatitis C virus infection status in a sample of people who inject drugs in Sydney and Canberra, Australia. Gibbs D; Grebely J; Sutherland R; Larney S; Butler K; Dietze PM; Starr M; Peacock A Drug Alcohol Rev; 2021 Nov; 40(7):1349-1353. PubMed ID: 33759276 [TBL] [Abstract][Full Text] [Related]
18. Eliminating hepatitis C in Australia: a novel model of hepatitis C testing and treatment for people who inject drugs at a medically supervised injecting facility. MacIsaac MB; Whitton B; Hubble A; Cogger S; Penn M; Weeks A; Elmore K; Pemberton D; Anderson J; Howard R; McKeever U; Papaluca T; Hellard ME; Stoove M; Wilson D; Pedrana A; Doyle J; Clark N; Holmes J; Thompson AJ Med J Aust; 2023 Apr; 218(6):256-261. PubMed ID: 36919230 [TBL] [Abstract][Full Text] [Related]
19. Hepatitis C virus micro-elimination in people who inject drugs: Challenges and chance in Taiwan and worldwide. Tai CM; Yu ML Kaohsiung J Med Sci; 2024 Feb; 40(2):112-118. PubMed ID: 38010851 [TBL] [Abstract][Full Text] [Related]
20. The Potential Reach of Opioid Substitution Settings to Deliver HCV Care to People Who Inject Drugs in Australia. Butler K; Day C; Dietze P; Bruno R; Alati R; Burns L J Subst Abuse Treat; 2015 Nov; 58():90-4. PubMed ID: 26117080 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]